Dyslipidemia International Survey-China

NCT01732952 | Unknown DMC

• 1 other identifier: 0000-271-0
• Study Type: observational
• Target: 25,000
• Locations: 1 country
• Sites: 1

Brief Summary

This cross-sectional, non-interventional, and observational study will assess the lipid profile of patients who have been taking lipid-modifying drugs (i.e., proportion of patients achieving treatment to goal according to national and international lipid management guidelines) during a single visit to their physicians on an outpatient basis in 6 representative geo-economic regions in China: Northeast, North, East, South, Southwest, and Northwest; and within each region, in three tiers of hospitals: tier 3 (primary or teaching hospitals), tier 2 (secondary or city level hospitals), and tier 1 (community hospitals/health centers). The investigators will primarily be cardiologists, endocrinologists, neurologists, gerontologists, internists, or other physicians who are representative of the general population of physicians managing patients with dyslipidemia and/or at high risk for cardiovascular events likely to be treated with lipid-modifying drugs. Demographic data, cardiovascular risk factors, a history of cardiovascular disease and cardiovascular treatments will be documented in a single visit through patient clinical examination and chart review. DYSIS-China is part of a string of epidemiological studies that share the same master protocol, which has been conducted in different countries mainly in Europe and Canada. The analysis of the pooled studies including overall data and cross-country comparisons is the subject of a distinct protocol.

Conditions

the Prevalence,Lipid Abnormalities,

Keywords

the prevalence,lipid abnormalities,CV risks

Outcome Measures

Primary Outcomes (1)

• the prevalence and types of persistent lipid abnormalities in patients aged > 45 years treated with a lipid-modifying drug

  6 months

Secondary Outcomes (1)

• assess patient characteristics, including CV risk levels, in the subsets of patients with persistent lipid abnormalities

  6months

Other Outcomes (1)

• explore a potential relationship between the persistence of lipid abnormalities and the local known (historical) prevalence of CV morbidity/mortality

  6months

Study Arms (1)

regions,hospitals,age, gender, risk levels, comorbidity,

Eligibility Criteria

• Age: 45 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

1. Patient is an outpatient \> 45 years of age 2. Patient is currently\* treated with a statin 3. Patient has a documented fasting lipid profile (\> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months 4. Patient agrees to participate in the study by giving informed consent. * Patient is already being treated with a lipid-modifying drug just before the visit. Patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included.

You may qualify if:

• Patient is an outpatient \> 45 years of age
• Patient is currently\* treated with a statin
• Patient has a documented fasting lipid profile (\> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months
• Patient agrees to participate in the study by giving informed consent.
• Patient is already being treated with a lipid-modifying drug just before the visit. Patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included.

You may not qualify if:

• \. Patient is currently participating in a clinical trial.

Sponsors & Collaborators

• Chinese Society of Cardiology: lead

Study Sites (1)

Peiking University People' Hospital

Beijing, Beijing Municipality, 100044, China

RECRUITING

Related Publications (2)

• Chen Y, Yin C, Li Q, Yu L, Zhu L, Hu D, Sun Y. Misuse of Aspirin and Associated Factors for the Primary Prevention of Cardiovascular Disease. Front Cardiovasc Med. 2021 Sep 3;8:720113. doi: 10.3389/fcvm.2021.720113. eCollection 2021.

  PMID: 34540919 DERIVED

• Yan X, Li Y, Dong Y, Wu Y, Li J, Bian R, Hu D. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy. Lipids Health Dis. 2019 Jan 29;18(1):32. doi: 10.1186/s12944-019-0974-y.

  PMID: 30696435 DERIVED

Study Officials

• Hu da yi, Dr.

  Chinese Society of Cardiology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hu da yi, Dr.

CONTACT

8601088324876; dayi.hu@medmail.com.cn

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chinese Society of Cardiology

Study Record Dates

• First Submitted: November 20, 2012
• First Posted: November 26, 2012
• Study Start: February 1, 2012
• Primary Completion: April 1, 2012
• Study Completion: December 1, 2012
• Last Updated: November 26, 2012

Record last verified: 2012-11

Locations

CN (1)